AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3588662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29530107 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification (IBM)
Number of subjects: 41
Study 29530107 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control (PC)
Number of subjects: 41
Study 29267668 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 60
Study 29267668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study 25935783 — intervention group
Group type: EXPERIMENTAL
Intervention: TrimoSan gel (applied vaginally twice weekly)
Number of subjects: 184
Study 25935783 — intervention group
Group type: COMPARATOR
Intervention: No gel (standard pessary care)
Number of subjects: 184
Study 25935783 — intervention group
Group type: EXPERIMENTAL
Intervention: TrimoSan gel
Number of subjects: 184
Study 25935783 — intervention group
Group type: COMPARATOR
Intervention: No gel
Number of subjects: 184
Study 23370697 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhalation during the lift
Number of subjects: 36
Study 23370697 — intervention group
Group type: COMPARATOR
Intervention: Inhalation during the lift
Number of subjects: 36
Study 23370697 — intervention group
Group type: COMPARATOR
Intervention: Sham (unconstrained coordination)
Number of subjects: 36
Study 21226970 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Community Based Care (CCBC) + Facility Based Care (FBC)
Number of subjects: 282
Study 21226970 — intervention group
Group type: COMPARATOR
Intervention: Facility Based Care (FBC)
Number of subjects: 282
Study 18071341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet plus sibutramine (10 mg per day)
Number of subjects: 59
Study 18071341 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet only
Number of subjects: 59
Study 16863011 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose sertaconazole vaginal tablet (500 mg)
Number of subjects: 40
Study 16863011 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3-dose econazole vaginal tablet (150 mg)
Number of subjects: 40
Study 14681094 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hypothermia with circulatory arrest
Number of subjects: 20
Study 14681094 — intervention group
Group type: COMPARATOR
Intervention: Deep hypothermia with low flow
Number of subjects: 20
Study 10673309 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha 2b alone
Number of subjects: 70
Study 10673309 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha 2b plus 200 mg ketoprofen three times a week
Number of subjects: 70
Study 10673309 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b plus 200 mg ketoprofen twice a day
Number of subjects: 70
Study 9487346 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 25 micrograms
Number of subjects: 16
Study 9487346 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms
Number of subjects: 16
Study 9487346 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 100 micrograms
Number of subjects: 16
Study 9487346 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 400 micrograms
Number of subjects: 16
Study 9487346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7648112 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vacuum drainage
Number of subjects: 78
Study 7648112 — intervention group
Group type: COMPARATOR
Intervention: High vacuum drainage
Number of subjects: 78
Study 2719462 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of ciprofloxacin twice daily for 5 days
Number of subjects: 30
Study 2719462 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of ciprofloxacin twice daily for 10 to 14 days
Number of subjects: 30
Study 2719462 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of ciprofloxacin twice daily plus 300 mg of rifampin twice daily for 21 days
Number of subjects: 30
Study 141237 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine 0.4 mg/kg
Number of subjects: 400
Study 141237 — intervention group
Group type: EXPERIMENTAL
Intervention: alcuroium 0.3 mg/kg
Number of subjects: 400
Study 141237 — intervention group
Group type: EXPERIMENTAL
Intervention: gallamine 1.8 mg/kg
Number of subjects: 400
Study 141237 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium
Number of subjects: 400
Study 141237 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 0.8 mg/kg
Number of subjects: 400
Study 31279278 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage (5g/100ml curry) - single meal
Number of subjects: 6
Study 31279278 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage (5g/100ml curry) - multiple meals
Number of subjects: 6
Study 31279278 — intervention group
Group type: COMPARATOR
Intervention: Low dosage (1g/100ml curry) - single meal or multiple meals
Number of subjects: 6
Study 28355706 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock salt aerosol therapy
Number of subjects: 65
Study 28355706 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment (control group)
Number of subjects: 65
Study 26032440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish group (fatty fish consumption)
Number of subjects: 83
Study 26032440 — intervention group
Group type: COMPARATOR
Intervention: Control group (meat, chicken, pork)
Number of subjects: 83
Study 25091666 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of Rotarix vaccine (n=45)
Number of subjects: 90
Study 25091666 — intervention group
Group type: EXPERIMENTAL
Intervention: Five doses of Rotarix vaccine (n=45)
Number of subjects: 90
Study 25091666 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine responders
Number of subjects: 90
Study 23068586 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric blood-flow stimulator (VEINOPLUS)
Number of subjects: 26
Study 23068586 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 26
Study 19411529 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey respondents rating the importance of oral health
Number of subjects: 1636
Study 19411529 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey respondents comparing oral health to diabetes
Number of subjects: 1636
Study 19411529 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey respondents comparing oral health to heart disease
Number of subjects: 1636
Study 19411529 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey respondents comparing oral health to arthritis
Number of subjects: 1636
Study 17208601 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 1223
Study 17208601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223
Study 15831783 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg (n = 12)
Number of subjects: 16
Study 15831783 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 16
Study 11810416 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (T‐E)
Number of subjects: 50
Study 11810416 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen (E)
Number of subjects: 50
Study 11810416 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen plus progestogen (E‐P)
Number of subjects: 50
Study 9535437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilutional ultrafiltration during and modified ultrafiltration after cardiopulmonary bypass
Number of subjects: 24
Study 9535437 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrafiltration
Number of subjects: 24
Study 9180950 — intervention group
Group type: EXPERIMENTAL
Intervention: 8OU of BoTox injected in four quadrants (1 ml in each quadrant‐20 U/ml) (n = 8)
Number of subjects: 13
Study 9180950 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution as placebo injected in the same way (n = 5)
Number of subjects: 13
Study 1827020 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg twice daily)
Number of subjects: 9
Study 7325403 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 80
Study 7325403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31521613 — intervention group
Group type: EXPERIMENTAL
Intervention: CHMI-derived parasites from volunteer groups receiving different PfSPZ dose and route
Number of subjects: 0
Study 31521613 — intervention group
Group type: EXPERIMENTAL
Intervention: CHMI-derived parasites
Number of subjects: 0
Study 31521613 — intervention group
Group type: COMPARATOR
Intervention: Pre-mosquito strain used for PfSPZ generation
Number of subjects: 0
Study 28095505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 5-year home visiting parenting program
Number of subjects: 0
Study 28095505 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25349264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratunnel femoral fixation with 2 bioabsorbable Rigidfix pins (cross‐pin fixation)
Number of subjects: 70
Study 25349264 — intervention group
Group type: COMPARATOR
Intervention: Extratunnel femoral fixation with 1 EndoButton cortical button per bundle
Number of subjects: 70
Study 24148985 — intervention group
Group type: EXPERIMENTAL
Intervention: Beveled group (short bevel [45°, 1-2 mm long] prepared with a diamond bur)
Number of subjects: 42
Study 24148985 — intervention group
Group type: COMPARATOR
Intervention: Non-beveled group (control)
Number of subjects: 42
Study 22832528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (up to 150 mg per day)
Number of subjects: 89
Study 22832528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 19455052 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐EPO
Number of subjects: 58
Study 16769582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive antithrombin III (ATIII) replacement therapy
Number of subjects: 162
Study 16769582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high dose defibrotide (60 mg/day) and ATIII replacement therapy
Number of subjects: 162
Study 16769582 — intervention group
Group type: COMPARATOR
Intervention: No specific VOD prophylaxis or therapy (Control)
Number of subjects: 162
Study 15545790 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg
Number of subjects: 1609
Study 15545790 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestin
Number of subjects: 1609
Study 15545790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1609
Study 10929273 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg daily
Number of subjects: 4
Study 10929273 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg daily
Number of subjects: 4
Study 10929273 — intervention group
Group type: COMPARATOR
Intervention: Low-dose pimozide 2 mg daily
Number of subjects: 4
Study 10929273 — intervention group
Group type: COMPARATOR
Intervention: Low-dose pimozide 4 mg daily
Number of subjects: 4
Study 1632479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmalgen
Number of subjects: 0
Study 1632479 — intervention group
Group type: EXPERIMENTAL
Intervention: Allpyral
Number of subjects: 0
Study 1632479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6465511 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (0.6 mg/kg before induction, 0.4 mg/kg +/- 0.2 mg/kg before termination)
Number of subjects: 20
Study 6465511 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 20
Study 31432575 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH followed by OST
Number of subjects: 26
Study 31432575 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by OST
Number of subjects: 26
Study 30157940 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment
Number of subjects: 0
Study 30157940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26803357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (ecologic physical activity intervention)
Number of subjects: 379
Study 26803357 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 379
Study 26803357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (girls)
Number of subjects: 379
Study 26803357 — intervention group
Group type: COMPARATOR
Intervention: Control group (girls)
Number of subjects: 379
Study 26803357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (boys)
Number of subjects: 379
Study 26803357 — intervention group
Group type: COMPARATOR
Intervention: Control group (boys)
Number of subjects: 379
Study 25208756 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide (30 mg once a week, n=504)
Number of subjects: 779
Study 25208756 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (10 U once a day, n=241)
Number of subjects: 779
Study 25208756 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 779
Study 25208756 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 779
Study 22703646 — intervention group
Group type: EXPERIMENTAL
Intervention: Super EBA
Number of subjects: 260
Study 22703646 — intervention group
Group type: COMPARATOR
Intervention: MTA
Number of subjects: 260
Study 20106567 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeldicks light intervention (n=34; 6 months)
Number of subjects: 66
Study 20106567 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=32; no intervention for 6 months)
Number of subjects: 66
Study 17868490 — intervention group
Group type: EXPERIMENTAL
Intervention: GOSPRO
Number of subjects: 2
Study 17868490 — intervention group
Group type: EXPERIMENTAL
Intervention: PDXPRO
Number of subjects: 2
Study 17868490 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO
Number of subjects: 2
Study 15986945 — intervention group
Group type: EXPERIMENTAL
Intervention: F2000 with F2000 self-etching primer/adhesive (F2000SE group)
Number of subjects: 90
Study 15986945 — intervention group
Group type: EXPERIMENTAL
Intervention: F2000 with Single Bond (F2000SB group)
Number of subjects: 90
Study 15986945 — intervention group
Group type: COMPARATOR
Intervention: Silux Plus with Single Bond (SiluxSB group)
Number of subjects: 90
Study 15986945 — intervention group
Group type: EXPERIMENTAL
Intervention: F2000
Number of subjects: 90
Study 15986945 — intervention group
Group type: EXPERIMENTAL
Intervention: F2000SE
Number of subjects: 90
Study 12893713 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) group: 30 minutes of supervised exercise at 70% of target heart rate for five days of a seven-day period.
Number of subjects: 24
Study 12893713 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise (NEX) group: No exercise intervention.
Number of subjects: 24
Study 10402153 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cues
Number of subjects: 0
Study 10402153 — intervention group
Group type: COMPARATOR
Intervention: Control cues
Number of subjects: 0
Study 9101901 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (early elective operations)
Number of subjects: 46
Study 9101901 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 46
Study 1662796 — intervention group
Group type: EXPERIMENTAL
Intervention: M37 vaccine 10(4) PFU
Number of subjects: 282
Study 1662796 — intervention group
Group type: EXPERIMENTAL
Intervention: M37 vaccine 10(5) PFU
Number of subjects: 282
Study 1662796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 4031977 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with BCNU
Number of subjects: 556
Study 4031977 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy without BCNU
Number of subjects: 556
Study 4031977 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision for AAF
Number of subjects: 556
Study 4031977 — intervention group
Group type: COMPARATOR
Intervention: Biopsy for AAF
Number of subjects: 556
Study 31476161 — intervention group
Group type: EXPERIMENTAL
Intervention: Twendee X (TwX)
Number of subjects: 78
Study 31476161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 29228101 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 403
Study 29228101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 27975350 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (radiofrequency kyphoplasty, nucleotomy, spondylodesis)
Number of subjects: 139
Study 27975350 — intervention group
Group type: EXPERIMENTAL
Intervention: PainDetect questionnaire
Number of subjects: 139
Study 27975350 — intervention group
Group type: EXPERIMENTAL
Intervention: Oswestry Index questionnaire (ODI)
Number of subjects: 139
Study 27975350 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS)
Number of subjects: 139
Study 27975350 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 139
Study 25227830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-minute brief physician counselling session to quit smoking
Number of subjects: 163
Study 25227830 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counselling)
Number of subjects: 163
Study 23762354 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric irrigation with 2 L saline solution before ESD
Number of subjects: 50
Study 23762354 — intervention group
Group type: COMPARATOR
Intervention: No irrigation (regular group)
Number of subjects: 50
Study 23762354 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric irrigation with saline solution
Number of subjects: 50
Study 21951354 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDIATRIC PRO‐SELF©: Pain Control Program
Number of subjects: 0
Study 21951354 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive nursing support
Number of subjects: 0
Study 19115593 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of HES 130/0.4 (Gr II : n = 61)
Number of subjects: 120
Study 19115593 — intervention group
Group type: COMPARATOR
Intervention: 1 liter of LR (Gr I: n = 59)
Number of subjects: 120
Study 17000364 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 26
Study 17000364 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnant women (control group)
Number of subjects: 26
Study 14562117 — intervention group
Group type: EXPERIMENTAL
Intervention: interferon (IFN)‐alpha
Number of subjects: 400
Study 14562117 — intervention group
Group type: EXPERIMENTAL
Intervention: chemotherapy (hydroxyurea (HU))
Number of subjects: 400
Study 14562117 — intervention group
Group type: EXPERIMENTAL
Intervention: chemotherapy (busulfan)
Number of subjects: 400
Study 14562117 — intervention group
Group type: EXPERIMENTAL
Intervention: allografting
Number of subjects: 400
Study 11211850 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative speech task
Number of subjects: 115
Study 8776909 — intervention group
Group type: EXPERIMENTAL
Intervention: Near patient test for CRP
Number of subjects: 181
Study 8776909 — intervention group
Group type: COMPARATOR
Intervention: Beckman Array for CRP
Number of subjects: 181
Study 1385618 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary expectancies for stimulus changes or repetitions in random tone series (Experiment 1 and Experiment 2)
Number of subjects: 0
Study 1385618 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary expectancies for stimulus changes or repetitions in random tone series (Experiment 2)
Number of subjects: 0
Study 1385618 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled expectancy process (reflected mainly in RT)
Number of subjects: 0
Study 1385618 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic expectancy process (reflected in P300 amplitude)
Number of subjects: 0
Study 6340085 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg
Number of subjects: 120
Study 6340085 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 60 mg
Number of subjects: 120
Study 6340085 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 120
Study 6340085 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 50-100 mg
Number of subjects: 120
Study 30270489 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM intervention
Number of subjects: 92
Study 29960105 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking combined with non-nutritive sucking
Number of subjects: 60
Study 29960105 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritive sucking alone
Number of subjects: 60
Study 27583591 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir concentrations <1 mg/L
Number of subjects: 195
Study 27583591 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir concentrations ≥1 mg/L
Number of subjects: 195
Study 27583591 — intervention group
Group type: COMPARATOR
Intervention: nevirapine concentrations
Number of subjects: 195
Study 25457928 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone cognitive-behavioral therapy (TCBT)
Number of subjects: 72
Study 25457928 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic-based face-to-face CBT
Number of subjects: 72
Study 25457928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TCBT and face-to-face CBT
Number of subjects: 72
Study 22395273 — intervention group
Group type: EXPERIMENTAL
Intervention: Unassisted PNF stretching with isometric contractions
Number of subjects: 13
Study 22395273 — intervention group
Group type: EXPERIMENTAL
Intervention: Unassisted PNF stretching with concentric contractions
Number of subjects: 13
Study 22395273 — intervention group
Group type: EXPERIMENTAL
Intervention: Unassisted PNF stretching with eccentric contractions
Number of subjects: 13
Study 22395273 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-assisted isometric PNF
Number of subjects: 13
Study 22395273 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 13
Study 22395273 — intervention group
Group type: COMPARATOR
Intervention: All stretching conditions
Number of subjects: 13
Study 20133013 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 2.5%
Number of subjects: 479
Study 20133013 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75%
Number of subjects: 479
Study 20133013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 479